Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3530866

Nc1cc(Oc2ccc(-c3nnc(Nc4ccc(Cl)c(C(F)(F)F)c4)o3)cc2)nc(N)n1.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.48
CDK8 P49336 3/20 0.42
GSK3B P49841 3/20 0.40
NOTUM Q6P988 1/20 0.40
CETP P11597 2/20 0.39
BRAF P15056 4/20 0.39
RAF1 P04049 4/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HDAC3 O15379 2/20 0.38
HDAC4 P56524 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC7 Q8WUI4 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC10 Q969S8 2/20 0.38
HDAC11 Q96DB2 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC9 Q9UKV0 2/20 0.38
HDAC5 Q9UQL6 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534025 0.94 KDR (0.47) KDRCDK8GSK3BNOTUMCETP
Trifluoroacetic Acid SCHEMBL3531719 0.84 KDR (0.49) KDRCDK8GSK3BNOTUMBRAF
Trifluoroacetic Acid SCHEMBL3528686 0.82 RAF1 (0.46) KDRCDK8GSK3BNOTUMCETP
SCHEMBL12057524 0.81 GSK3B (0.47) GSK3BKDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL3534184 0.80 RAF1 (0.51) KDRCDK8GSK3BNOTUMBRAF
SCHEMBL3529698 0.80 GSK3B (0.60) GSK3BKDM4EALDH1A1
SCHEMBL627855 0.79 GSK3B (0.51) KDRGSK3BBRAFRAF1KDM4E
SCHEMBL3534650 0.79 GSK3B (0.45) KDRGSK3BKDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL3532518 0.79 RAF1 (0.63) KDRCDK8GSK3BBRAFRAF1
SCHEMBL3531460 0.77 GSK3B (0.46) GSK3BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372971-B2 Heterocyclic compounds and methods of use TARGEGEN, INC. (US) 2013-02-12 US disclosed
US-20120220584-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE TARGEGEN, INC. (US) 2012-08-30 US disclosed
US-8084618-B2 Heterocyclic compounds and methods of use TARGEGEN, INC. (US) 2011-12-27 US disclosed
US-20100330069-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE TARGEGEN, INC. (US) 2010-12-30 US disclosed
US-7652051-B2 Heterocyclic compounds and methods of use TARGEGEN, INC. (US) 2010-01-26 US disclosed
US-20060079526-A1 Heterocyclic compounds and methods of use TARGEGEN, INC. (US) 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220584-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AADAC, NISCH, PAICS KDR 4380/4885CDK8 110/4885GSK3B 2586/4885
US-20060079526-A1 Heterocyclic compounds and methods of use AADAC, NISCH, PAICS KDR 4380/4885CDK8 110/4885GSK3B 2586/4885
US-20100330069-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AADAC, NISCH, PAICS KDR 4380/4885CDK8 110/4885GSK3B 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.